Ovid Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OVID research report →
Companywww.ovidrx.com
Ovid Therapeutics Inc. , a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies.
- CEO
- Margaret Alexander
- IPO
- 2017
- Employees
- 23
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $315.20M
- P/E
- -7.29
- P/S
- 44.26
- P/B
- 0.89
- EV/EBITDA
- -4.68
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.51%
- Op Margin
- -670.25%
- Net Margin
- -339.33%
- ROE
- -22.51%
- ROIC
- -22.59%
Growth & Income
- Revenue
- $7.25M · 1181.27%
- Net Income
- $-17,414,000 · 34.12%
- EPS
- $-0.24 · 35.14%
- Op Income
- $-42,439,000
- FCF YoY
- 31.58%
Performance & Tape
- 52W High
- $3.10
- 52W Low
- $0.27
- 50D MA
- $2.55
- 200D MA
- $1.72
- Beta
- 0.18
- Avg Volume
- 3.24M
Get TickerSpark's AI analysis on OVID
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 7, 26 | PAPADOPOULOS STELIOS | other | 17,578 |
| Apr 7, 26 | Friedman Bart | other | 8,789 |
| Apr 7, 26 | Fitzgerald Kevin Joseph | other | 17,578 |
| Mar 23, 26 | LEVIN JEREMY M | other | 47,333 |
| Mar 23, 26 | LEVIN JEREMY M | other | 47,333 |
| Feb 26, 26 | ALEXANDER MARGARET A. | other | 1,435,000 |
| Feb 23, 26 | ALEXANDER MARGARET A. | sell | 11,656 |
| Feb 26, 26 | PAPADOPOULOS STELIOS | other | 65,000 |
| Feb 26, 26 | LEVIN JEREMY M | other | 957,000 |
| Feb 26, 26 | Fitzgerald Kevin Joseph | other | 65,000 |
Our OVID Coverage
We haven't published any research on OVID yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OVID Report →